References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–333
- The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen on postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701–1712
- Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
- Fournier A, Berrino F, Riboli E, Avenal V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114: 448–454
- Chevallier T, Daures J P, Micheletti M C, Reginster J Y, Groupe MISSION. Méthodologie de l'enquête MISSION (Ménopause,rISque de cancer du SeIn, mOrbidité et prévaleNce). J Gynecol Obstet Biol Reprod 2005; 34: 658–665
- Espié M, Mares P, De Reilhac P, Chevallier T, Daurès J -P. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study. Gynecol Endocrinol 2006; 22: 423–431
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059
- Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002; 288: 58–66
- Chlebowski R T, Hendrix S L, Langer R D, Stefanick M L, Gass M, Lane D, Rodabough R J, Gilligan M A, Cyr M G, Thomson C A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. J Am Med Assoc 2003; 289: 3243–3253
- Fabre A, Fournier A, Mesrine S, Desreux J, Gompel A, Boutron-Ruault M C, Clavel-Chapelon F. Oral progestagens before menopause and breast cancer risk. Br J Cancer 2007; 96: 841–844